Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1238 participants.
Also called NCT02387229
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 1,238 participants
- Sponsor
- Registry
-
NCT02387229
-
- Other papers using this trial's data
- Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Terminated
Technical summary
Registry record NCT02387229. Randomized; quadruple masking; primary purpose prevention. Start 2015-03 (actual); primary completion 2024-05-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF
- Acronym
- BRAIN-AF
- Condition
- ATRIAL FIBRILLATION
- Intervention (Drug)
- Rivaroxaban
- Intervention (Other)
- standard of care
- Lead sponsor
- Montreal Heart Institute
- Collaborator
- Canadian Stroke Prevention Intervention Network
- Collaborator
- The Montreal Health Innovations Coordinating Center (MHICC)
- Collaborator
- Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
- Collaborator
- Montreal Heart Institute Foundation
- Collaborator
- Canadian Institutes of Health Research (CIHR)
- Collaborator
- Hewitt Foundation
Record details
- Record id
cardio:ct-nct02387229- Content hash
e316e4dae4f02c4792ca90aaacc1aa34e1fcab0809703bde250056e055701af7